Rocket Pharmaceuticals, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Rocket Pharmaceuticals, Inc. (RCKT) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 1.97 million shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-05-07
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-03-31 was 1.97M shares, a 23.84% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-09-30 was 1.97M shares, a 23.84% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 1.97M shares, a 23.84% decline year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-03-31 was 2.59M shares, a 0.00% change year-over-year.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2025 was 1.97M shares, a 23.84% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 2.59M shares, a 0.00% change from fiscal 2023.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 2.59M shares, a 4.89% decline from fiscal 2022.
- Rocket Pharmaceuticals, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2022 was 2.72M shares, a 123.41% increase from fiscal 2021.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | 1.97M shares 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | 1.97M shares 10-K · filed 2026-02-26 | |||||
| 2025-09-30 | 1.97M shares 10-Q · filed 2025-11-06 | 1.97M shares 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 1.97M shares 10-Q · filed 2025-08-07 | 1.97M shares 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | 2.59M shares 10-Q · filed 2026-05-07 | |||||
| 2024-12-31 | 2.59M shares 10-K · filed 2026-02-26 | |||||
| 2024-09-30 | 2.59M shares 10-Q · filed 2025-11-06 | 2.59M shares 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 2.59M shares 10-Q · filed 2025-08-07 | 2.59M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 2.59M shares 10-Q · filed 2025-05-08 | |||||
| 2023-12-31 | 2.59M shares 10-K · filed 2025-02-27 | |||||
| 2023-09-30 | 2.59M shares 10-Q · filed 2024-11-07 | 2.59M shares 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | 2.59M shares 10-Q · filed 2023-08-09 | 2.59M shares 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 2.60M shares 10-Q · filed 2024-05-07 | |||||
| 2022-12-31 | 2.72M shares 10-K · filed 2025-02-27 | |||||
| 2022-09-30 | 1.22M shares 10-Q · filed 2023-11-07 | 1.22M shares 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | 1.22M shares 10-Q · filed 2023-08-09 | 1.22M shares 10-Q · filed 2023-08-09 | ||||
| 2022-03-31 | 1.22M shares 10-Q · filed 2023-05-05 | |||||
| 2021-12-31 | 1.22M shares 10-K · filed 2024-02-27 | |||||
| 2021-09-30 | 610.44K shares 10-Q · filed 2022-11-04 | 911.73K shares 10-Q · filed 2021-11-05 | 610.44K shares 10-Q · filed 2022-11-04 | 911.73K shares 10-Q · filed 2021-11-05 | ||
| 2021-06-30 | 610.44K shares 10-Q · filed 2022-08-09 | 610.44K shares 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 610.44K shares 10-Q · filed 2022-05-06 | |||||
| 2020-12-31 | 610.44K shares 10-K · filed 2023-02-28 | |||||
| 2020-09-30 | 14.10K shares 10-Q · filed 2021-11-05 | 14.10K shares 10-Q · filed 2021-11-05 | ||||
| 2020-06-30 | 14.10K shares 10-Q · filed 2021-08-09 | 14.10K shares 10-Q · filed 2021-08-09 | ||||
| 2020-03-31 | 14.10K shares 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 14.10K shares 10-K · filed 2022-02-28 | |||||
| 2018-12-31 | 14.10K shares 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |